RxDoctor Payments Data

Justina Raimer, PA

Physician Assistant · Largo, FLNPI 1477941623

Payments from drug & device makers

$5,365in general payments, 2019–2025

Across 285 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$616
  • Amgen$544
  • Boehringer Ingelheim$496
  • Johnson & Johnson$460
  • Boston Scientific$454
  • Pfizer$367
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,365 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$46,333
Medicare patients
272
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$204,568
XareltoRivaroxaban75$84,378
EntrestoSacubitril/Valsartan48$71,456
Repatha SureclickEvolocumab32$45,353
JardianceEmpagliflozin15$20,363
FarxigaDapagliflozin Propanediol19$17,411
OzempicSemaglutide13$15,964
MultaqDronedarone Hcl12$13,427
Repatha SyringeEvolocumab12$8,909
Rosuvastatin Calcium205$2,691
Metoprolol Succinate198$2,615
Ranolazine ErRanolazine30$2,507
Atorvastatin Calcium233$2,159
Ezetimibe90$1,851
ClopidogrelClopidogrel Bisulfate205$1,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$367$204,568203 claims
Johnson & JohnsonXarelto$460$84,37875 claims
NovartisEntresto$616$71,45648 claims
Boehringer IngelheimJardiance$496$20,36315 claims
AstraZenecaFarxiga$255$17,41119 claims
Novo NordiskOzempic$64$15,96413 claims
Sanofi-aventis U.S. LLCMultaq$171$13,42712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →